p53 and MDR1 co-expression in breast cancer
1996

Co-expression of p53 and P-glycoprotein in Breast Cancer

Sample size: 50 publication Evidence: moderate

Author Information

Author(s): SC Linn, AH Honkoop, K Hoekman, P van der Valk, HM Pinedo, G Giaccone

Primary Institution: Free University Hospital

Hypothesis

We investigated whether p53 and P-gp are simultaneously expressed in primary breast cancer cells and analyzed the impact of the co-expression on patients' prognosis.

Conclusion

Nuclear p53 accumulation is often associated with P-gp expression in primary breast cancer, and simultaneous expression of p53 and P-gp is associated with shorter survival in locally advanced breast cancer patients.

Supporting Evidence

  • Co-expression of p53 and P-gp was the strongest prognostic factor for shorter survival.
  • 75% of P-gp-positive patients were also p53 positive.
  • Locally advanced breast cancers had a higher frequency of P-gp and p53 positivity compared to operable cancers.

Takeaway

This study found that when two proteins, p53 and P-glycoprotein, are both present in breast cancer cells, it usually means the cancer is more aggressive and harder to treat.

Methodology

Immunohistochemistry was used to investigate P-gp expression and nuclear p53 accumulation in 20 operable and 30 locally advanced breast cancers.

Limitations

The study had a small sample size and relied on tumor samples obtained after chemotherapy for survival analysis.

Participant Demographics

Patients included 20 with operable breast cancer and 30 with locally advanced breast cancer, with a median age of 63 for operable and 49 for locally advanced.

Statistical Information

P-Value

P=0.003; P=0.0004; P=0.048; P=0.002; P=0.004; P=0.0007

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication